Report of Foreign Issuer (6-k)
September 07 2018 - 9:59AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
07 September
2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc ('
GSK
')
Awards under the GSK Deferred Investment Award
programme
In accordance with Disclosure Guidance and Transparency Rule
3.1.4R(1)(a) GSK today announces a change in the interests
of Persons Discharging Managerial Responsibilities ('PDMR')
in notional shares of GSK as a result of awards made under
the GlaxoSmithKline Deferred Investment Award programme (the
'Programme') on 6 September 2018. The awards under the Programme
will vest on 14 February 2021.
Awards are made over notional American Depositary Shares and
Ordinary Shares. Vesting is subject to the individuals not having
served GSK notice or having been terminated by GSK for cause. The
awards will not accrue dividends, and on vesting, will be paid in
cash. Executive Directors are not eligible to receive awards
under the Programme.
Both awards relate to the PDMRs' employment prior to their being
appointed to GSK's Corporate Executive Team.
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr J Ford
|
b)
|
Position/status
|
SVP & General Counsel
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of thefinancial
instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the transaction
|
An award of notional ADSs under the Company's Deferred Investment
Award.
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$39.78
|
6,320
|
|
|
|
|
|
d)
|
Aggregated information
|
n/a (single transaction)
|
Aggregated volumePrice
|
|
e)
|
Date
of the transaction
|
2018-09-06
|
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr R Simard
|
b)
|
Position/status
|
President, Pharmaceutical Supply Chain
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of thefinancial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of thetransaction
|
An award of notional Ordinary Shares under the Company's Deferred
Investment Award.
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.254
|
11,060
|
|
|
|
|
|
d)
|
Aggregated information
|
n/a (single transaction)
|
Aggregated volumePrice
|
|
e)
|
Date
of the transaction
|
2018-09-06
|
f)
|
Place of the
transaction
|
n/a
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: September
07, 2018
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024